Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Completed
National Alliance for Research on Schizophrenia and Depression
Phase 4
2007-03-01
The study consists of measurement of antidepressant-induced excessive sweating and its
treatment with an experimental medication, terazosin (approved for hypertension), that will
be added to the antidepressant. This study is for people who take an antidepressant due to a
depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks,
with one week of baseline measurement and four weeks of treatment with the study medication.
The study is based on the hypothesis that terazosin will be effective in reducing the
severity of excessive sweating caused by antidepressant treatment, and will have minimal
side-effects.
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Completed
Thomas Jefferson University
Phase 4
2007-03-01
The study consists of measurement of antidepressant-induced excessive sweating and its
treatment with an experimental medication, terazosin (approved for hypertension), that will
be added to the antidepressant. This study is for people who take an antidepressant due to a
depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks,
with one week of baseline measurement and four weeks of treatment with the study medication.
The study is based on the hypothesis that terazosin will be effective in reducing the
severity of excessive sweating caused by antidepressant treatment, and will have minimal
side-effects.
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Completed
Boehringer Ingelheim
Phase 4
1998-08-01
1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg
daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the
signs and symptoms of benign prostatic hyperplasia (BPH)
2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in
comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the
symptoms of benign prostatic hyperplasia
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
